Biotech Values

[mcbio]

Shares may gain about $2 on a positive FDA ruling, RBC Capital Markets analyst Michael Yee said. FDA approval will attract investors who avoided the shares when Benlysta's fate remained uncertain, he said.

If that statement is anywhere close to accurate, then there's no way in hell I'd play HGSI in front of the FDA's decision on Benlysta. Do you really want to risk what would in all likelihood be substantial downside if any hiccup with the FDA for a measly $2 increase? That seems absurd to me.